Translational advances in p53 targeted cancer therapy from molecular mechanisms to clinical application

作者
Sarad Pawar Naik Bukke,Gali Avinash Kumar,P. Pravallika,M. Kasi Viswanadh,Ananda Kumar Chettupalli,Chandrashekar Thalluri,Neha Gupta
出处
期刊:Discover Oncology [Springer Nature]
标识
DOI:10.1007/s12672-026-05819-y
摘要

The p53 tumor suppressor is among the most valid oncogenes targets. Although translation of p53-based therapies has had inconsistent results regardless of strong preclinical validation, it remains evident that a clear gap exists between the biological rationale and therapeutic durability. This review is a critical assessment of p53-directed strategies, like mutant p53 reactivation, activation of suppressed wild-type p53 via MDM2/MDMX inhibition, gene replacement strategies, and targeting the loss of p53. This review is not to enlist therapeutic agents or pathways, but instead to evaluate the constraints for translation, i.e. pathway dependency, and limitations on the therapeutic window, and trial design mismatch, that have chosen clinical outcomes. Experiences of failures of late-stage clinical trials show that p53 targeting/restoration is often not sufficient to produce a lasting tumor remission. The future directions are in allele-specific mutant targeting, patient stratification based on biomarkers, adaptive trial design, and rational combination strategies that increase the level of stress beyond tolerable levels. The structurally druggable alleles are only a small minority of TP53-mutant disease, with the Y220C hotspot accounting for approximately 1.8% of TP53-mutant tumors and interim phase II data for rezatapopt showing objective responses of 33–34% with a median duration of response of 6.2–7.6 months. In contrast, pan-mutant agents are expected to have a strong effect on redox modulation as well as on structural refolding, accounting for the fact that it gets diluted in the unselected cohorts. New proximity inducing modalities, such as PROTAC degraders of mutants, molecular glues and p53 mRNA nanotherapy, expand the therapeutic toolbox beyond refolding, and proof that p53 restoration remodels the tumor immune microenvironment also offers a rationale for combination with immune checkpoint blockade.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陆地完成签到,获得积分10
1秒前
3秒前
酷波er的应助被开朗紫采纳,获得10
3秒前
鼻毛好胜发布了新的文献求助10
3秒前
泍泍完成签到 ,获得积分10
4秒前
波波子发布了新的文献求助20
4秒前
自然的赛凤完成签到,获得积分20
5秒前
下雨之后完成签到 ,获得积分10
6秒前
6秒前
DYL完成签到,获得积分10
7秒前
SciGPT的应助被彩色的明雪采纳,获得10
8秒前
从容傲柏完成签到,获得积分10
9秒前
raoarao发布了新的文献求助10
9秒前
一一完成签到 ,获得积分10
10秒前
10秒前
11秒前
Ava的应助被ao123采纳,获得10
11秒前
哈基米的应助被自然的赛凤采纳,获得30
11秒前
以钛的应助被哈哈哈采纳,获得10
12秒前
Naruto完成签到 ,获得积分10
13秒前
积木师whale完成签到,获得积分10
13秒前
Jobs完成签到,获得积分10
13秒前
OVOV完成签到,获得积分10
14秒前
14秒前
15秒前
15秒前
15秒前
15秒前
15秒前
15秒前
15秒前
15秒前
15秒前
星城浮轩完成签到,获得积分10
15秒前
15秒前
开朗紫发布了新的文献求助10
16秒前
16秒前
自信寻冬完成签到 ,获得积分10
17秒前
小马甲的应助被爱听歌芷蝶采纳,获得10
17秒前
黃偉倫完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552